People channel feed – Endpoints News

People channel feed

Biotech bound, Liz Barrett passes Novartis' top oncology job to Susanne Schaffert

7 years ago

John Johnson is back trying his hand as a turnaround artist for a troubled biotech. Can he win this time?

7 years ago

Novartis CAR-T chief drops out of Big Pharma, joins the great migration to a favorite biotech destination

7 years ago

Tesaro execs split $304M windfall from $5.1B GlaxoSmithKline buyout

7 years ago

Flagship-backed Foghorn woos Bristol-Myers vet Carl Decicco to direct its 'gene traffic control' platform

7 years ago

Third Rock, Takeda-backed Ambys ushers in ex-NGM Bio president Jeff Jonker as CEO

7 years ago

'Idea Man' Paul Allen leaves behind plan to unscramble human immunology

7 years ago

Shinichi Tamura reclaims the helm at Sosei as CEO Peter Bains hits the exit

7 years ago

Clive Meanwell gives way to new CEO as activist investor Alex Denner shakes up The Medicines Company

7 years ago

Gilead locks in Daniel O'Day as CEO, tapping the Roche vet to rejuvenate growth

7 years ago

With fresh company building lessons from Ablynx, Edwin Moses is ready to try it again as chair of neoantigen biotech Achilles

7 years ago

Disgraced VC Steven Burrill heads to prison with 30-month sentence for fraud, tax evasion

7 years ago

Newly named Abeona chief Carsten Thiel booted after the board accuses him of misconduct involving colleagues

7 years ago

Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline

7 years ago

Jury finds former Aveo CFO David Johnston liable for scheme to mislead investors

7 years ago

Is AstraZeneca looking for the ideal candidate to replace Pascal Soriot?

7 years ago

Billionaire gifts Harvard a historic $200M to 'expedite' translational biomedical research work

7 years ago

The resurrection of LUM001: Mike Grey gets his drug back from Shire — along with $120M to gamble on PhIII trials

7 years ago

Fresh from a $72M raise, Jeff Aronin's new lead rare disease drug is flagged as a failure

7 years ago

Rattled by setbacks, Celgene turns to ex-Merck R&D star Alise Reicin to repair its damaged development rep

7 years ago

Buyout deal looming, Novo Nordisk raids AstraZeneca for a new chief to run its struggling biopharma business

7 years ago

Following the exodus at Immunocore, Eliot Forster takes the reins at F-star — how long before the crossover and an IPO?

7 years ago

#BIIS18 Interview: OrbiMed Asia's Jonathan Wang on his upbringing, deciding against a consulting career, blunt advice for Chinese entrepreneurs, and more

7 years ago

Ex-Celgene dealmaker George Golumbeski joins up to guide Carrick on its cancer drug quest — and maybe an IPO as well

7 years ago

First page Previous page 83 84 858687 88 89 Next page Last page